| 608 |
446: Reduction of testosterone |
348: Malformation, Male reproductive tract |
Nov 29, 2016 |
Dec 2, 2016 |
None
|
| 405 |
348: Malformation, Male reproductive tract |
406: decreased, Fertility |
Nov 29, 2016 |
Dec 2, 2016 |
1 AOP
|
| 995 |
853: Changes/Inhibition, Cellular Homeostasis and Apoptosis |
139: N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects |
Nov 29, 2016 |
Dec 2, 2016 |
1 AOP
|
| 996 |
139: N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects |
854: Alterations, Cellular proliferation / hyperplasia |
Nov 29, 2016 |
Dec 2, 2016 |
1 AOP
|
| 997 |
854: Alterations, Cellular proliferation / hyperplasia |
856: Formation, Hepatocellular and Bile duct tumors |
Nov 29, 2016 |
Dec 2, 2016 |
1 AOP
|
| 9 |
8: Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity |
179: Decrease, Fatty acid β-oxidation |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 77 |
66: Activation, ChREBP |
89: Synthesis, De Novo Fatty Acid (FA) |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 70 |
60: Induction, Chitin degradation and resorption |
238: Induction, Pre-mature molting |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 69 |
57: Proliferation, Cell proliferation in the absence of cytotoxicity |
142: Hyperplasia, Hyperplasia |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 62 |
52: Decreased, Calcium influx |
341: Impairment, Learning and memory |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 61 |
51: Inhibition, Ca++ ATPase |
50: Increase, Ca++ (intracellular) |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 60 |
50: Increase, Ca++ (intracellular) |
178: Mitochondrial electron transport chain, disrupted |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 59 |
49: Reduction, Ca and HCO3 transport to shell gland |
106: Reduction, Eggshell thickness |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 51 |
39: Increased Cholinergic Signaling |
360: Decrease, Population growth rate |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 19 |
18: Activation, AhR |
80: Up Regulation, CYP1A1 |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 18 |
18: Activation, AhR |
17: Altered expression of AHR/ARNT pathway-dependent genes |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 17 |
17: Altered expression of AHR/ARNT pathway-dependent genes |
80: Up Regulation, CYP1A1 |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 16 |
17: Altered expression of AHR/ARNT pathway-dependent genes |
317: Altered, Cardiovascular development/function |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 93 |
77: Production, Critical Metabolites (CGA 330050 and CGA 265307) |
164: Induction, Liver “Dysfunctional” Changes by CGA 330050 |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 116 |
103: Increase, EcR hyperactivation |
60: Induction, Chitin degradation and resorption |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 104 |
84: Up Regulation, CYP1B1 |
3: Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 96 |
80: Up Regulation, CYP1A1 |
209: Peptide Oxidation |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 95 |
79: Inhibition, Cyclooxygenase activity |
243: Reduction, Prostaglandin E2 concentration |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 108 |
87: Release, Cytokine |
149: Increase, Inflammation |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 197 |
183: Abnormal, Morphogenesis |
366: Increased, Structural malformations |
Nov 29, 2016 |
Dec 3, 2016 |
None
|